$15.14
3.81% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
IE00B91XRN20
Symbol
PRTA
Sector
Industry

Prothena Corp. Plc Stock price

$15.14
-0.74 4.66% 1M
-5.39 26.25% 6M
-21.20 58.34% YTD
-22.74 60.03% 1Y
-32.29 68.08% 3Y
-0.86 5.38% 5Y
-5.79 27.66% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.60 3.81%
ISIN
IE00B91XRN20
Symbol
PRTA
Sector
Industry

Key metrics

Market capitalization $814.66m
Enterprise Value $306.89m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.30
P/S ratio (TTM) P/S ratio 6.11
P/B ratio (TTM) P/B ratio 1.52
Revenue growth (TTM) Revenue growth -5.41%
Revenue (TTM) Revenue $133.35m
EBIT (operating result TTM) EBIT $-168.18m
Free Cash Flow (TTM) Free Cash Flow $-154.91m
Cash position $519.26m
EPS (TTM) EPS $-2.48
P/E forward negative
P/S forward 5.80
EV/Sales forward 2.18
Short interest 23.59%
Show more

Is Prothena Corp. Plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Prothena Corp. Plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Prothena Corp. Plc forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a Prothena Corp. Plc forecast:

Buy
80%
Hold
20%

Financial data from Prothena Corp. Plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
133 133
5% 5%
100%
- Direct Costs 17 17
123% 123%
13%
116 116
13% 13%
87%
- Selling and Administrative Expenses 33 33
22% 22%
25%
- Research and Development Expense 234 234
20% 20%
176%
-151 -151
44% 44%
-113%
- Depreciation and Amortization 17 17
123% 123%
13%
EBIT (Operating Income) EBIT -168 -168
49% 49%
-126%
Net Profit -132 -132
80% 80%
-99%

In millions USD.

Don't miss a Thing! We will send you all news about Prothena Corp. Plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Prothena Corp. Plc Stock News

Positive
Investors Business Daily
10 days ago
Prothena stock catapulted Thursday after the company's Roche-partnered Parkinson's treatment showed promise in a midstage study. The post Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease appeared first on Investor's Business Daily.
Neutral
Business Wire
10 days ago
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced results from PADOVA study conducted by partner Roche investigating prasinezumab in early-stage Parkinson's disease.
Neutral
Business Wire
about 2 months ago
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today reported financial results for the third quarter and first nine months of 2024 and provided business highlights.
More Prothena Corp. Plc News

Company Profile

Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Gene Kinney
Employees 173
Founded 1969
Website www.prothena.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today